| 1 |
Development of lead compound for Leber hereditary optic neuropathy |
| Small Molecules |
Leber hereditary optic neuropathy |
NQO1 |
Lead |
Curome Bioscience |
RS-2023-00259507 |
|
| 2 |
Investigational New Drug Application Profiling of CGK012, a PKCα activator, for treating age.related macular degeneration |
| Small Molecules |
Macular degeneration |
Protein kinase Cα / Wnt/β.catenin 신호전달 저해 |
Preclinical |
AREZ |
RS-2023-00259081 |
|
| 3 |
Non-clinical research for the development of dry macular degeneration |
| Small Molecules |
Dry AMD |
RIPK1 |
Preclinical |
Mother’s Pharmaceutical Co., Ltd |
RS-2023-00219642 |
|
| 4 |
Lead identification for retinal diseases using selective NO delivery compounds |
| Small Molecules |
Retinal vein occlusion |
Co, Fe |
Hit |
Ulsan National Institute of Science & Technology |
RS-2023-00217242 |
|
| 5 |
Discovery of first-in-Class AMD treatment for dry eye using Autophagy activation |
| Small Molecules |
Dry macular degeneration |
Autophage |
Lead |
VasThera |
RS-2022-00166507 |
|
| 6 |
Future Medicine FM101-Oral Glaucoma Treatment |
| Small Molecules |
Glaucoma, Ocular hypertension |
A3AR |
Phase 2 |
Future Medicine Co., Ltd. |
HN22C0520 |
|
| 7 |
Development of DWRX2008 as a Novel Therapeutic for Intractable Ocular Angiogenesis |
| Small Molecules |
Diabetic Retinopathy |
SGLT2 |
Preclinical |
Daewoong Therapeutics |
HN22C0450 |
|
| 8 |
To develop the lead of a new oral drug for age-related macular degeneration |
| Small Molecules |
Age-related macular degeneration |
PDK4 |
Hit |
Kyungpook National University |
HN21C0923 |
|
| 9 |
Nonclinical drug candidates targeting TRAP1 to treat diabetic retinopathy |
| Small Molecules |
Diabetic retinopathy |
TRAP1 |
Candidate |
SMARTIN BIO Inc. |
HN21C0882 |
|
| 10 |
Lead development of orally available drug for diabetic retinopathy targeting TGase 2 to inhibit vascular leakage |
| Small Molecules |
Diabetic retinopathy |
TGase2 |
Hit |
Daegu Gyyeongbuk Medical Innovation Foundation |
HN21C1155 |
|
